MTOR and endometrial cancer: Chemotherapy-naïve endometrial cancer patients treated with temsirolimus, an mTOR inhibitor, achieved a preliminary response rate of 26% according to the National Cancer Institute of Canada; this result was not correlated to PTEN status as evaluated by immunohistochemistry [92].